Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant and adjuvant recombinant interleukin-21 in stage III malignant melanoma
2006-005350-79Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2008
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of recombinant human interleukin 21 in melanoma, sponsored by Novo Nordisk. Primary endpoint: Complete pathological response rate in sentinel lymph nodes. Started Jul 2008; status: completed.
02
Drugs
recombinant human interleukin 21
03
Conditions
melanoma
Beyond the preview
Go deeper on 2006-005350-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005350-79.